Summary
This is a phase 1b prospective, single arm, open-label trial determining the efficacy and feasibility of using a response-guided approach to help guide neoadjuvant chemotherapy in subjects with Stage IB, II or Stage III adenocarcinoma of the stomach or gastroesophageal junction (GEA).
Official Title
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) - a Phase Ib Feasibility Trial
Keywords
Gastroesophageal Adenocarcinoma, Folfox protocol, IFL protocol, folfirinox, Paclitaxel, Carboplatin, Docetaxel, Irinotecan, Home Environment, Nivolumab, pembrolizumab, durvalumab, Trastuzumab, FLOT, FOLFOX, FOLFIRI, PACLITAXEL with or without CARBOPLATIN, DOCETAXEL and IRINOTECAN (alone or combined), NIVOLUMAB (alone or when added to a regimen above), PEMBROLIZUMAB (alone or when added to a regimen above)